Summary

Middle East and Africa postpartum hemorrhage treatment devices market is expected to reach USD 81.35 million by 2032 from USD 53.18 million in 2024, growing at a CAGR of 5.5% in the forecast period of 2025 to 2032.

Market Segmentation:
Middle East and Africa Postpartum Hemorrhage Treatment Devices Market, , By Type (Uterine Balloon Tamponade, Uniject Prefilled Injection System, Non-Pneumatic Anti-Shock Garment, Vacuum-Induced Hemorrhage Control Devices, and Others), Condition (Major Postpartum Hemorrhage (More Than 1000 ML), Minor Postpartum Hemorrhage (500-1000 ML), and Massive Postpartum Hemorrhage (2000 ML or More), and Secondary Postpartum Hemorrhage), Patient Type (Primary PPH and Secondary PPH), End User (Hospitals, Maternity Centers, Specialty Clinics, Home Care Settings, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others), Country (Saudi Arabia, South Africa, Egypt, U.A.E., Israel, Kuwait, and Rest of Middle East and Africa) - Industry Trends & Forecast To 2032


Overview of Middle East and Africa Postpartum Hemorrhage Treatment Market Dynamics:

Driver

• Rising incidence of postpartum hemorrhage

Restraint

• Side effects associated with the postpartum hemorrhage treatment
Opportunity

• Training and educational programs for proper use of PPH treatment devices

• Market Players:

The key market players operating in the Middle East and Africa postpartum hemorrhage treatment market are listed below:

• Coagulant Therapeutics
• Sterimed Group
• RevMedx
• BD
• Organon group of companies
• Laborie
• CooperCompanies
• Belmont Medical Technologies
• Utah Medical Products, Inc
• ANGIPLAST PRIVATE LIMITED
• 3rd Stone Design
• Advin Health Care

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 INTRODUCTION 59
1.1 OBJECTIVES OF THE STUDY 59
1.2 MARKET DEFINITION 59
1.3 OVERVIEW OF THE MIDDLE EAST AND AFRICA POSTPARTUM HEMORRHAGE TREATMENT DEVICES MARKET 60
1.4 LIMITATIONS 61
1.5 MARKETS COVERED 61
2 MARKET SEGMENTATION 64
2.1 MARKETS COVERED 64
2.2 GEOGRAPHICAL SCOPE 65
2.3 YEARS CONSIDERED FOR THE STUDY 66
2.4 CURRENCY AND PRICING 66
2.5 DBMR TRIPOD DATA VALIDATION MODEL 67
2.6 MULTIVARIATE MODELLING 70
2.7 TYPE LIFELINE CURVE 71
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 72
2.9 DBMR MARKET POSITION GRID 73
2.10 VENDOR SHARE ANALYSIS 74
2.11 MARKET END USER COVERAGE GRID 75
2.12 SECONDARY SOURCES 76
2.13 ASSUMPTIONS 76
3 EXECUTIVE SUMMARY 77
4 PREMIUM INSIGHTS 81
4.1 PESTAL ANALYSIS 83
4.2 PORTERS FIVE FORCES ANALYSIS 84
4.3 INDUSTRY INSIGHTS 85
4.3.1 MICRO AND MACROECONOMIC FACTORS 85
4.3.2 PENETRATION AND GROWTH PROSPECT MAPPING 85
4.3.3 KEY PRICING STRATEGIES 85
4.4 COST ANALYSIS BREAKDOWN 86
4.5 TECHNOLOGY ROADMAP 86
4.6 VALUE CHAIN ANALYSIS 87
4.7 OPPORTUNITY MAP ANALYSIS 87
4.8 HEALTHCARE ECONOMY 87
4.9 REIMBURSEMENT FRAMEWORK 88
4.10 TARIFFS AND ITS IMPACT ON THE MARKET 89
4.10.1 DEFINITION AND IMPORTANCE OF TARIFFS IN THE HEALTHCARE SECTOR 89
4.10.2 MIDDLE EAST AND AFRICA VS. REGIONAL TARIFF STRUCTURES 89
4.10.3 IMPACT OF TARIFFS ON HEALTHCARE COSTS AND ACCESSIBILITY 89
4.10.4 TARIFF REGULATIONS IN KEY MARKETS 90
4.10.4.1 MEDICARE/MEDICAID TARIFF POLICIES 90
4.10.4.2 CMS PRICING MODELS 90
4.10.4.3 OTHERS 90
4.10.5 TARIFFS ON MEDICAL DEVICES & EQUIPMENT 90
4.10.5.1 IMPORT/EXPORT DUTIES ON MEDICAL EQUIPMENT 90
4.10.5.2 IMPACT ON PRICING AND AVAILABILITY OF HIGH-END MEDICAL TECHNOLOGY 90
4.10.5.3 CASE STUDIES OF TARIFF CHANGES AFFECTING THE INDUSTRY 91
4.10.6 COST BURDEN ON HOSPITALS AND HEALTHCARE FACILITIES 91
4.10.7 TARIFF EXEMPTIONS AND INCENTIVES 91
4.10.8 DUTY-FREE IMPORTS FOR ESSENTIAL MEDICINES AND VACCINES 91
4.10.9 IMPACT OF TRADE WARS ON THE HEALTHCARE SUPPLY CHAIN 92
4.10.10 ROLE OF FREE TRADE AGREEMENTS (FTAS) IN REDUCING TARIFFS 92
5 REGULATORY FRAMEWORK 93
6 MARKET OVERVIEW 96
6.1 DRIVERS 98
6.1.1 RISING INCIDENCE OF POSTPARTUM HAEMORRHAGE 98
6.1.2 ONGOING TECHNOLOGICAL ADVANCEMENTS FOR POSTPARTUM HEMORRHAGE TREATMENTS 99
6.1.3 RISING BIRTH RATES ASSOCIATED WITH AN INCREASE IN THE NUMBER OF POSTPARTUM HEMORRHAGE 100
6.1.4 REGULATORY SUPPORT AND APPROVALS ASSOCIATED WITH THE TREATMENT DEVICES 101
6.2 RESTRAINTS 102
6.2.1 SIDE EFFECTS ASSOCIATED WITH THE POSTPARTUM HEMORRHAGE TREATMENT 102
6.2.2 LIMITED RESEARCH AND DEVELOPMENT FOR PPH TREATMENT 103
6.3 OPPORTUNITIES 104
6.3.1 TRAINING AND EDUCATIONAL PROGRAMS FOR PROPER USE OF PPH TREATMENT DEVICES 104
6.3.2 SUPPORT FROM GOVERNMENTAL AND NON-GOVERNMENTAL ORGANIZATIONS IN PPH DEVICE ADOPTION 105
6.3.3 TELEMEDICINE INTEGRATION TO ENHANCE POSTPARTUM HEMORRHAGE DEVICE USE 106
6.4 CHALLENGES 107
6.4.1 ENVIRONMENTAL IMPACT AND DISPOSAL ISSUES OF SINGLE-USE PPH DEVICES 107
6.4.2 STERILITY CHALLENGES AND INFECTION RISKS IN PPH DEVICES 108
7 MIDDLE EAST AND AFRICA POSTPARTUM HEMORRHAGE TREATMENT DEVICES MARKET, BY TYPE 109
7.1 OVERVIEW 110
7.2 UTERINE BALLOON TAMPONADE 113
7.2.1 BAKRI BALLOON 114
7.2.1.1 BAKRI POSTPARTUM BALLOON 114
7.2.1.2 BAKRI POSTPARTUM BALLOON WITH RAPID INSTILLATION COMPONENTS 114
7.2.2 FOLEY CATHETER 115
7.2.2.1 STANDARD FOLEY CATHETER 115
7.2.2.2 CONDOM-LOADED FOLEY CATHETER 115
7.3 UNIJECT PREFILLED INJECTION SYSTEM 116
7.3.1 OXYTOCIN-BASED INJECTION SYSTEM 116
7.3.2 CARBETOCIN-BASED INJECTION SYSTEM 116
7.4 NON-PNEUMATIC ANTI-SHOCK GARMENT 117
7.4.1 STANDARD NON-PNEUMATIC ANTI-SHOCK GARMENT 118
7.4.1.1 MEDIUM 118
7.4.1.2 LARGE 118
7.4.2 MODIFIED NON-PNEUMATIC ANTI-SHOCK GARMENT 118
7.4.2.1 MEDIUM 118
7.4.2.2 LARGE 118
7.5 VACUUM-INDUCED HEMORRHAGE CONTROL DEVICES 119
7.5.1 JADA SYSTEM 119
7.5.2 OTHERS 119
7.6 OTHERS 120
7.6.1 COMPRESSION DEVICES 121
7.6.1.1 B-LYNCH 121
7.6.1.2 HAYMAN 121
7.6.1.3 OTHER 121
7.6.2 UTERINE ARTERY LIGATION PRODUCTS 121
7.6.3 OTHERS 121
8 MIDDLE EAST AND AFRICA POSTPARTUM HEMORRHAGE TREATMENT DEVICES MARKET, BY PATIENT TYPE 122
8.1 OVERVIEW 123
8.2 PRIMARY PPH 126
8.3 SECONDARY PPH 127
9 MIDDLE EAST AND AFRICA POSTPARTUM HEMORRHAGE TREATMENT DEVICES MARKET, BY CONDITION 128
9.1 OVERVIEW 129
9.2 MAJOR POSTPARTUM HEMORRHAGE (MORE THAN 1000 ML) 132
9.3 MINOR POSTPARTUM HEMORRHAGE (500-1000 ML) 133
9.4 MASSIVE POSTPARTUM HEMORRHAGE (2000 ML OR MORE) 134
9.5 SECONDARY POSTPARTUM HEMORRHAGE 134
10 MIDDLE EAST AND AFRICA POSTPARTUM HEMORRHAGE TREATMENT DEVICES MARKET, BY DISTRIBUTION CHANNEL 135
10.1 OVERVIEW 136
10.2 DIRECT TENDER 139
10.3 RETAIL SALES 140
10.3.1 OFFLINE SALES 140
10.3.2 ONLINE SALES 140
10.4 OTHERS 141
11 MIDDLE EAST AND AFRICA POSTPARTUM HEMORRHAGE TREATMENT DEVICES MARKET, BY END USER 142
11.1 OVERVIEW 143
11.2 HOSPITALS 146
11.2.1 PUBLIC HOSPITALS 147
11.2.1.1 TIER 2 147
11.2.1.2 TIER 3 147
11.2.1.3 TIER 1 147
11.2.2 PRIVATE HOSPITALS 148
11.2.2.1 TIER 2 148
11.2.2.2 TIER 3 148
11.2.2.3 TIER 1 148
11.3 MATERNITY CENTERS 149
11.4 SPECIALTY CLINICS 150
11.5 HOME CARE SETTINGS 150
11.6 OTHERS 151
12 MIDDLE EAST AND AFRICA POSTPARTUM HEMORRHAGE TREATMENT DEVICES MARKET, BY REGION 152
12.1 MIDDLE EAST AND AFRICA 154
12.1.1 SOUTH AFRICA 161
12.1.2 SAUDI ARABIA 167
12.1.3 EGYPT 173
12.1.4 U.A.E. 179
12.1.5 KUWAIT 185
12.1.6 QATAR 191
12.1.7 OMAN 197
12.1.8 BAHRAIN 203
12.1.9 REST OF MIDDLE EAST AND AFRICA 209
13 MIDDLE EAST AND AFRICA POSTPARTUM HEMORRHAGE TREATMENT DEVICES MARKET: COMPANY LANDSCAPE 210
13.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA 210
14 SWOT ANALYSIS 211
15 COMPANY PROFILES 212
15.1 BD 212
15.1.1 COMPANY SNAPSHOT 212
15.1.2 REVENUE ANALYSIS 213
15.1.3 COMPANY SHARE ANALYSIS 213
15.1.4 SOLUTION PORTFOLIO 214
15.1.5 RECENT NEWS 214
15.2 ORGANON GROUP OF COMPANIES 215
15.2.1 COMPANY SNAPSHOT 215
15.2.2 REVENUE ANALYSIS 215
15.2.3 COMPANY SHARE ANALYSIS 216
15.2.4 PRODUCT PORTFOLIO 216
15.2.5 RECENT DEVELOPMENTS/NEWS 217
15.3 LABORIE 218
15.3.1 COMPANY SNAPSHOT 218
15.3.2 COMPANY SHARE ANALYSIS 218
15.3.3 PRODUCT PORTFOLIO 219
15.3.4 RECENT DEVELOPMENT 219
15.4 COOPERCOMPANIES 220
15.4.1 COMPANY SNAPSHOT 220
15.4.2 REVENUE ANALYSIS 220
15.4.3 COMPANY SHARE ANALYSIS 221
15.4.4 PRODUCT PORTFOLIO 221
15.4.5 RECENT DEVELOPMENT 221
15.5 BELMONT MEDICAL TECHNOLOGIES 222
15.5.1 COMPANY SNAPSHOT 222
15.5.2 COMPANY SHARE ANALYSIS 222
15.5.3 PRODUCT PORTFOLIO 223
15.5.4 RECENT DEVELOPMENT 223
15.6 ADVIN HEALTH CARE 224
15.6.1 COMPANY SNAPSHOT 224
15.6.2 PRODUCT PORTFOLIO 224
15.6.3 RECENT DEVELOPMENTS 224
15.7 ANGIPLAST PRIVATE LIMITED 225
15.7.1 COMPANY SNAPSHOT 225
15.7.2 PRODUCT PORTFOLIO 225
15.7.3 RECENT DEVELOPMENT 225
15.8 COAGULANT THERAPEUTICS 226
15.8.1 COMPANY SNAPSHOT 226
15.8.2 PIPELINE PORTFOLIO 226
15.8.3 RECENT DEVELOPMENT 226
15.9 KRISHCO MEDICAL PRODUCTS PVT. LTD 227
15.9.1 COMPANY SNAPSHOT 227
15.9.2 PRODUCT PORTFOLIO 227
15.9.3 RECENT DEVELOPMENT 228
15.10 MATERNOVA INC. 229
15.10.1 COMPANY SNAPSHOT 229
15.10.2 PRODUCT PORTFOLIO 229
15.10.3 RECENT DEVELOPMENT 229
15.11 REVMEDX 230
15.11.1 COMPANY SNAPSHOT 230
15.11.2 PRODUCT PORTFOLIO 230
15.11.3 RECENT DEVELOPMENT 230
15.12 3RD STONE DESIGN 231
15.12.1 COMPANY SNAPSHOT 231
15.12.2 PRODUCT PORTFOLIO 231
15.12.3 RECENT DEVELOPMENTS 231
15.13 STERIMED GROUP 232
15.13.1 COMPANY SNAPSHOT 232
15.13.2 PRODUCT PORTFOLIO 232
15.13.3 RECENT DEVELOPMENTS 232
15.14 UTAH MEDICAL PRODUCTS, INC. 233
15.14.1 COMPANY SNAPSHOT 233
15.14.2 REVENUE ANALYSIS 233
15.14.3 PRODUCT PORTFOLIO 234
15.14.4 RECENT DEVELOPMENTS 234
15.15 SINAPI BIOMEDICAL 235
15.15.1 COMPANY SNAPSHOT 235
15.15.2 PRODUCT PORTFOLIO 235
15.15.3 RECENT DEVELOPMENTS 235
16 QUESTIONNAIRE 236